Earnings Snapshot: AbbVie beats Q3 EPS and revenue views, raises full-year earnings guidan
AbbVie reported Q3 non-GAAP EPS of $3.82, exceeding estimates by $0.05, and revenue of $17.4B, surpassing expectations by $50M. The company raised its full-year earnings guidance. Analysts attributed the beat to strong performance of Skyrizi and Rinvoq, along with gains in oncology.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise may trigger buying interest and short‑term upside.
Market read
Strong Q3 results and raised guidance provide a clear trading catalyst for ABBV.
What to watch
Potential upcoming patent cliff could weigh on longer‑term outlook despite short‑term beat.
Background
AbbVie is a large‑cap U.S. biopharma company with key products Skyrizi and Rinvoq.
Ticker impact
AbbVie reported Q3 Non‑GAAP EPS of $3.82 beating estimates by $0.05 and revenue of $17.4B beating by $50M, while raising full‑year guidance.
upward pressure as investors price in the earnings beat and higher guidance
Both EPS and revenue beat, plus an upgrade to FY guidance, are fresh primary data for a large‑cap pharma.
Market effects
May boost sentiment for the broader pharma sector as earnings beat suggests resilience.
Positive for US healthcare stocks.
Limited to pharma investors; no broad macro effect.
Counterpoint
If the beat is already priced in, the stock could face short‑term profit taking.
Key entities
- CompanyAbbVie
U.S. biopharma firm reporting Q3 results.
